Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 8/2013

01.08.2013 | Original Paper

A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis

verfasst von: Cheng Xu, Zhehui Yan, Liang Zhou, Yuming Wang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Abstract

Backgrounds

Glypican-3(GPC3) has been reported as one of the most promising serum markers for hepatocellular carcinoma (HCC), while several studies have conflicting results for the diagnostic accuracy between GPC3 and alpha-fetoprotein (AFP).

Methods

Studies that explored the diagnostic value of GPC3 and AFP in HCC were searched in MEDLINE, EMBASE, PUBMED, the Cochrane Library and Chinese biomedical literature database (CBM). Sensitivity, specificity and other measures about the accuracy of serum GPC3 and AFP in the diagnosis of HCC were pooled using random effects models. Summary receiver operating characteristic curve (sROC) analysis was used to summarize the overall test performance.

Results

Ten studies were included in our meta-analysis. The pooled sensitivity for AFP and GPC3 is 51.9 % (95 % confidence interval (CI) 0.47–0.56) and 59.2 % (95 % CI 0.55–0.63), respectively, while the pooled specificity for AFP and GPC3 is 94 % (95 % CI 92.1–95.6 %) and 84.8 % (95 % CI 82–87.3 %), respectively. The pooled diagnostic odds ratio (DOR) for AFP and GPC3 were 23.4 (95 % CI 10.3–53.2) and 17.99 (95 % CI 5.4–60.4), respectively. Area under sROC for both AFP and GPC3 is 0.81 (95 % CI 0.77–0.84).

Conclusions

GPC3 is comparable to AFP as a serum marker for the diagnosis of HCC, combination of AFP and GPC3 can elevate the sensitivity of diagnosis.
Literatur
Zurück zum Zitat Beale G et al (2008) AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 8:200CrossRefPubMed Beale G et al (2008) AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 8:200CrossRefPubMed
Zurück zum Zitat Bh Y (2001) Chinese society of liver cancer: clinical diagnosis and staging criteria for primary hepatocellular carcinoma. Zhongguo Ganzangbing Zazhi 9:324–330 Bh Y (2001) Chinese society of liver cancer: clinical diagnosis and staging criteria for primary hepatocellular carcinoma. Zhongguo Ganzangbing Zazhi 9:324–330
Zurück zum Zitat Bian YZ et al (2011) Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 19(4):260–265PubMed Bian YZ et al (2011) Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 19(4):260–265PubMed
Zurück zum Zitat Capurro M, Filmus J (2005) Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res 65(1):372 (author reply 372–3)PubMed Capurro M, Filmus J (2005) Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res 65(1):372 (author reply 372–3)PubMed
Zurück zum Zitat Capurro M et al (2003) Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125(1):89–97CrossRefPubMed Capurro M et al (2003) Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125(1):89–97CrossRefPubMed
Zurück zum Zitat Capurro MI et al (2005) Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 65(14):6245–6254CrossRefPubMed Capurro MI et al (2005) Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 65(14):6245–6254CrossRefPubMed
Zurück zum Zitat Cleophas TJ, Zwinderman AH (2009) Meta-analyses of diagnostic studies. Clin-Chem-Lab-Med 47(11):1351–1354PubMed Cleophas TJ, Zwinderman AH (2009) Meta-analyses of diagnostic studies. Clin-Chem-Lab-Med 47(11):1351–1354PubMed
Zurück zum Zitat Dinnes J et al (2005) A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess 9(12):1–113 Dinnes J et al (2005) A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess 9(12):1–113
Zurück zum Zitat Ferlay J et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917CrossRefPubMed Ferlay J et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917CrossRefPubMed
Zurück zum Zitat Filmus J, Capurro M (2004) Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn 8(4):207–212PubMed Filmus J, Capurro M (2004) Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn 8(4):207–212PubMed
Zurück zum Zitat Filmus J, Selleck SB (2001) Glypicans: proteoglycans with a surprise. J Clin Invest 108:497–501PubMed Filmus J, Selleck SB (2001) Glypicans: proteoglycans with a surprise. J Clin Invest 108:497–501PubMed
Zurück zum Zitat Honest H, Khan KS (2002) Reporting of measures of accuracy in systematic reviews of diagnostic literature. BMC Health Serv Res 2:4CrossRefPubMed Honest H, Khan KS (2002) Reporting of measures of accuracy in systematic reviews of diagnostic literature. BMC Health Serv Res 2:4CrossRefPubMed
Zurück zum Zitat Huber R et al (1999) DNA methylation in transcriptional repression of two differentially expressed X-linked genes, GPC3 and SYBL1. Proc Natl Acad Sci USA 96(2):616–621CrossRefPubMed Huber R et al (1999) DNA methylation in transcriptional repression of two differentially expressed X-linked genes, GPC3 and SYBL1. Proc Natl Acad Sci USA 96(2):616–621CrossRefPubMed
Zurück zum Zitat Komori H et al (2010) Assessment of serum GPC3 as a tumor marker for hepatocellular carcinoma and malignant melanoma. Nihon Rinsho 68(Suppl 7):833–836PubMed Komori H et al (2010) Assessment of serum GPC3 as a tumor marker for hepatocellular carcinoma and malignant melanoma. Nihon Rinsho 68(Suppl 7):833–836PubMed
Zurück zum Zitat Li BD et al (2006) Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells. Zhonghua Wai Ke Za Zhi 44(7):458–462PubMed Li BD et al (2006) Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells. Zhonghua Wai Ke Za Zhi 44(7):458–462PubMed
Zurück zum Zitat Li P et al (2009) Diagnosis of Glypican-3 protein for primary hepatic cancer is superior to alpha-fetoprotein. Hep Intl 3(1):155 Li P et al (2009) Diagnosis of Glypican-3 protein for primary hepatic cancer is superior to alpha-fetoprotein. Hep Intl 3(1):155
Zurück zum Zitat Li P et al (2010) Diagnostic value of serum AFP alone or in combination with glypican 3, VEGF or IGF-II for patients with primary hepatocellular carcinoma. World J Gastroenterol Li P et al (2010) Diagnostic value of serum AFP alone or in combination with glypican 3, VEGF or IGF-II for patients with primary hepatocellular carcinoma. World J Gastroenterol
Zurück zum Zitat Liu H et al (2010) Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol 16(35):4410–4415CrossRefPubMed Liu H et al (2010) Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol 16(35):4410–4415CrossRefPubMed
Zurück zum Zitat Malaguarnera G et al (2010) Serum markers of hepatocellular carcinoma. Dig Dis Sci 55(10):2744–2755CrossRefPubMed Malaguarnera G et al (2010) Serum markers of hepatocellular carcinoma. Dig Dis Sci 55(10):2744–2755CrossRefPubMed
Zurück zum Zitat Miao H et al (2007) Glypican-3 protein expression in serum and tissues and its clinical significance in hepatocellular carcinoma. World Chin J Digestol 15(21):2311–2315 Miao H et al (2007) Glypican-3 protein expression in serum and tissues and its clinical significance in hepatocellular carcinoma. World Chin J Digestol 15(21):2311–2315
Zurück zum Zitat Midorikawa Y et al (2003) Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 103(4):455–465CrossRefPubMed Midorikawa Y et al (2003) Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 103(4):455–465CrossRefPubMed
Zurück zum Zitat Moety HAAE et al (2011) Glypican-3 amino terminal marker for early detection of HCC. Hep Intl 5(1):435 Moety HAAE et al (2011) Glypican-3 amino terminal marker for early detection of HCC. Hep Intl 5(1):435
Zurück zum Zitat Moriguchi H, Sato C (2004) The values and limitations of glypican-3 as a novel tumor marker for hepatocellular carcinoma from clinical and economic viewpoints. Gastroenterology 127(2):679–680CrossRefPubMed Moriguchi H, Sato C (2004) The values and limitations of glypican-3 as a novel tumor marker for hepatocellular carcinoma from clinical and economic viewpoints. Gastroenterology 127(2):679–680CrossRefPubMed
Zurück zum Zitat Moses LE, Shapiro D, Littenberg B (1993) Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 12(14):1293–1316CrossRefPubMed Moses LE, Shapiro D, Littenberg B (1993) Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 12(14):1293–1316CrossRefPubMed
Zurück zum Zitat Nakatsura T, Nishimura Y (2005) Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs 19(2):71–77CrossRefPubMed Nakatsura T, Nishimura Y (2005) Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs 19(2):71–77CrossRefPubMed
Zurück zum Zitat Nakatsura T et al (2003) Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 306(1):16–25CrossRefPubMed Nakatsura T et al (2003) Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 306(1):16–25CrossRefPubMed
Zurück zum Zitat Nobuoka D et al (2010) Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. Oncol Rep 24(2):521–528PubMed Nobuoka D et al (2010) Postoperative serum alpha-fetoprotein level is a useful predictor of recurrence after hepatectomy for hepatocellular carcinoma. Oncol Rep 24(2):521–528PubMed
Zurück zum Zitat Ozkan H et al (2011) Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. J Clin Lab Anal 25(5):350–353CrossRefPubMed Ozkan H et al (2011) Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma. J Clin Lab Anal 25(5):350–353CrossRefPubMed
Zurück zum Zitat Qiao SS et al (2011) Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepatogastroenterology 58(110–111):1718–1724PubMed Qiao SS et al (2011) Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepatogastroenterology 58(110–111):1718–1724PubMed
Zurück zum Zitat Song F et al (2002) Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol 31(1):88–95CrossRefPubMed Song F et al (2002) Asymmetric funnel plots and publication bias in meta-analyses of diagnostic accuracy. Int J Epidemiol 31(1):88–95CrossRefPubMed
Zurück zum Zitat Sousa MR, Ribeiro AL (2009) Systematic review and meta-analysis of diagnostic and prognostic studies: a tutorial. Arq Bras Cardiol 92(3): 229–238, 235–245 Sousa MR, Ribeiro AL (2009) Systematic review and meta-analysis of diagnostic and prognostic studies: a tutorial. Arq Bras Cardiol 92(3): 229–238, 235–245
Zurück zum Zitat Sung YK et al (2003) Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci 94(3):259–262CrossRefPubMed Sung YK et al (2003) Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci 94(3):259–262CrossRefPubMed
Zurück zum Zitat Suzuki M et al (2010) Up-regulation of glypican-3 in human hepatocellular carcinoma. Anticancer Res 30(12):5055–5061PubMed Suzuki M et al (2010) Up-regulation of glypican-3 in human hepatocellular carcinoma. Anticancer Res 30(12):5055–5061PubMed
Zurück zum Zitat Tangkijvanich P et al (2010) Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol 25(1):129–137CrossRefPubMed Tangkijvanich P et al (2010) Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol 25(1):129–137CrossRefPubMed
Zurück zum Zitat Wei Z et al (2007) Detection of glypican 3 in serum and its clinical significance on the diagnosis of hepatocellular carcinoma. Tumor 27(9):679–682 Wei Z et al (2007) Detection of glypican 3 in serum and its clinical significance on the diagnosis of hepatocellular carcinoma. Tumor 27(9):679–682
Zurück zum Zitat Whiting P et al (2003) The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3:25CrossRefPubMed Whiting P et al (2003) The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 3:25CrossRefPubMed
Zurück zum Zitat Whiting P et al (2004) Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 140(3):189–202CrossRefPubMed Whiting P et al (2004) Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 140(3):189–202CrossRefPubMed
Zurück zum Zitat Yamauchi N et al (2005) The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 18(12):1591–1598PubMed Yamauchi N et al (2005) The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 18(12):1591–1598PubMed
Zurück zum Zitat Yan D et al (2011) Detection of alpha-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR. J Clin Lab Anal 25(2):113–117CrossRefPubMed Yan D et al (2011) Detection of alpha-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR. J Clin Lab Anal 25(2):113–117CrossRefPubMed
Zurück zum Zitat Yao M et al (2011) Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 10(3):289–294CrossRefPubMed Yao M et al (2011) Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 10(3):289–294CrossRefPubMed
Zurück zum Zitat Yasuda E et al (2010) Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatol Res 40(5):477–485CrossRefPubMed Yasuda E et al (2010) Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma. Hepatol Res 40(5):477–485CrossRefPubMed
Zurück zum Zitat Youssef MF et al (2010) Clinical utility of Glypican- 3 in hepatocellular carcinoma. Int J Integr Biol 10(1):41–47 Youssef MF et al (2010) Clinical utility of Glypican- 3 in hepatocellular carcinoma. Int J Integr Biol 10(1):41–47
Zurück zum Zitat Zamora J et al (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6:31CrossRefPubMed Zamora J et al (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6:31CrossRefPubMed
Zurück zum Zitat Zhang Q et al (2010) Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma. Clin Biochem 43(12):1003–1008CrossRefPubMed Zhang Q et al (2010) Development of a competitive radioimmunoassay for glypican-3 and the clinical application in diagnosis of hepatocellular carcinoma. Clin Biochem 43(12):1003–1008CrossRefPubMed
Zurück zum Zitat Zhu ZW et al (2001) Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 48(4):558–564CrossRefPubMed Zhu ZW et al (2001) Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 48(4):558–564CrossRefPubMed
Metadaten
Titel
A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis
verfasst von
Cheng Xu
Zhehui Yan
Liang Zhou
Yuming Wang
Publikationsdatum
01.08.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2013
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-013-1458-5

Weitere Artikel der Ausgabe 8/2013

Journal of Cancer Research and Clinical Oncology 8/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.